Arrowhead Pharmaceuticals, Inc.ARWR
What Arrowhead Pharmaceuticals, Inc. does.
The Company develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and modes of delivery, the Company’s therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes.
There are currently 18 Arrowhead discovered drug candidates in clinical trials ranging from early stage (Phase 1) to late stage (Phase 3). In addition, the company has a robust discovery stage pipeline which is capable of generating multiple new clinical candidates each year.
The Company recently achieved a transformational milestone with its first commercial launch in 2025, when the U.S. Food and Drug Administration ("FDA") approved REDEMPLO ® (plozasiran) as an adjunct to diet to reduce triglycerides in adults with Familial Chylomicronemia Syndrome ("FCS"). Additionally, phase 3 studies (SHASTA-3, SHASTA-4 and SHASTA-5) for severe hypertriglyceridemia ("sHTG") have been fully enrolled and the Company plans to file a supplemental NDA for this indication in 2026, pending successful completion of Phase 3 clinical studies. The Company has built a commercial organization to support marketing in FCS, a rare disease, and plans to progressively build its commercial capabilities to also support marketing in sHTG, a higher prevalence disease which will require a larger commercial footprint.
Revenue and profit, by fiscal year.
| Fiscal year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Revenue | $88.0M | $138.3M | $243.2M | $240.7M | $3.6M | $829.4M |
| Net income | -$84.6M | -$140.8M | -$176.1M | -$205.3M | -$599.5M | -$1.6M |
| Free cash flow | -$107.8M | $147.7M | -$188.9M | -$330.6M | -$604.3M | $156.9M |
More on ARWR.
- Arrowhead Pharmaceuticals, Inc. summary
- Arrowhead Pharmaceuticals, Inc. financial statements
- Arrowhead Pharmaceuticals, Inc. key metrics
- Arrowhead Pharmaceuticals, Inc. health scores and style box
- Arrowhead Pharmaceuticals, Inc. earnings
- Arrowhead Pharmaceuticals, Inc. dividends
- Arrowhead Pharmaceuticals, Inc. valuation
- Arrowhead Pharmaceuticals, Inc. ownership and insiders
- Arrowhead Pharmaceuticals, Inc. peers
Figures from Arrowhead Pharmaceuticals, Inc.'s filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.